Lupin is one of the top Pharma companies with an excellent Balance Sheet, Sales Revenue growth and a very good future.
From long term investment point of view, this is an excellent company to have in your portfolio and current levels of 1250 are an excellent entry.
One can add more if it dips further as this stock itself promises to give 20% + returns within or...
Although the ideas I share with you all revolve around currency pairs, I thought I'd share another specialty of mine: Biotech and pharma stock. If you're in the field, you may have already heard about Gilead having one of the best price to earning ratio of the major biotech companies. You may have also noticed the sharp decline that they experienced in the summer...
Can't get enough VDRM at these prices!
Anyone who has been following my posts knows I'm very long on this stock and coming back down to these prices is a pure gift.
With the CEO speaking at a large conference at the end of the month, lots of eyes will be on this company.
$$'s by December or sooner IMO.
Millionaires will be made!
The $TEVA chart just keeps getting better and better....
Quarterly chart is rejecting last 2 major lows with a pinbar with stoch RSI overbought
Ideally we bounce here to retest the fibs and form a right shoulder before complete capitulation.
If the H&S formation is confirmed $TEVA should head down to levels we haven't seen since the 90's ($10 and below)
Posted about this one a few weeks and am still holding all my shares plus a few more.
This will be 2017's big winner IMO. Low floaters move FAST. The company has revolutionary patents pending as well as great news released last Friday about their new products.
It's extremely undervalued, and I know for a fact strong hands like myself will continue buying up...
We appear to be bottoming at the neckline of a potential H&S. This thing is a monster and can be easily seen on the 6 month and yearly time frames.
You could buy the relief rally that takes us back up or wait for extra confirmation and sell the relief rally with a formation of that shoulder.
2017 price target is $1.25, analysis shows me we should reach 1.25 or higher in the next 12 months. I had to sell $RNVA for +10% here as this play is too good to pass up. Company is EXTREMELY undervalued given the things in the work for 2017. Several patents, topical Viagra in the works, entrance into the Medical Marijuana sector...Company should also fair well...
If you check the ideas I´ve posted, you can see the monthly GILD chart, were you can clearly see the stock is about to blow up and at a great entry price.
Right here you can see how the stock made 3 resistance levels, a few weeks ago it validated the second resistance and it just did with the first one.
Enter now or regret it later.
Go big or go home.
Ongoing Pharma/Drug Stance from Trump may force Indian Pharma Space into a short term downtrend, Aurobindo's foothold is strong in Europe than US, they plan to expand more in Europe than US. if available within Accumulation range, one should buy and hold for medium to long term!!
12.5.2016- $KBIO currently trading at 4.25. Potential once they receive PRV (Priority Review Voucher) for Benznidazole possibility for trading at $5-6. Stock jumped about $1 due to the Letter to Stakeholders by Dr. Cameron Durrant. I expect this stock to rise.
Disclosure: I am long $KBIO